Plant Variety Rights

(PVRs)

Experts in IP Protection for Plant Variety Inventions


Improvement of crop and ornamental species by genetic modification or modern breeding techniques remains a significant area of innovation. A number of IP rights may be suitable for protecting plant inventions, including patents, trade marks, plant Variety Rights (PVRs) and entry on the national list or common catalogue. Our experienced IP specialists are well placed to assist our clients in this area, having a wealth of practical experience.

In Europe, individual plant varieties that are distinct, uniform and stable can be protected either nationally or at European Community level. Separately, European and national patents can be obtained for plants and plant-related inventions which are not restricted to plant varieties per se, although certain plant breeding methods and plants obtained by those methods are excluded from patentability.  Despite the EU’s strict policies on growing genetically modified crops and uncertainty surrounding the use of genetic resources in plant breeding, there is considerable commercial interest in these technical areas and in IP protection for the output of biotech research and classical breeding programs.

Our expert IP team is led by Frances Salisbury, who has a PhD in plant molecular genetics. An expert in this field Frances has completed the official World Intellectual Property Organisation (WIPO) course on Plant Variety Protection under the UPOV Convention.

Read our Plant Variety Rights Law and Practice guide.

Read our blogs

Seeing double: the rise of biparatopic antibodies

Seeing double: the rise of biparatopic antibodies

by Emily Garnett

It’s no secret that antibody therapies are gaining ever-increasing popularity in the pharmaceutical industry. Worth a mere 0.3 billion USD in 1997, the global antibody therapeutics market has already ...

Crafting IP Strategies for Innovative Biotechs

Crafting IP Strategies for Innovative Biotechs

by Adam Gregory

Following his conversation with John Joson Ng for Nucleate Singapore Pulse, we speak to Adam Gregory about crafting effective IP strategies for biotech ventures, avoiding common pitfalls, and ...

Enzyme engineering with AI – the latest chapter (in a long story…)

Enzyme engineering with AI – the latest chapter (in a long story…)

by Simon Kremer

For those of us who studied Biochemistry at college, the classic active site “catalytic triad” of serine peptidases was often our first introduction to the fascinating world of enzymes (and also, ...

HutanBio: algae is the fuel of the future

HutanBio: algae is the fuel of the future

by Simon Kremer

Algae converts sunlight and carbon dioxide into flammable hydrocarbons, offering a like-for-like replacement for fossil fuels.

In vivo Cell Therapy: Breaking Free of the Chains of Ex Vivo Engineering

In vivo Cell Therapy: Breaking Free of the Chains of Ex Vivo Engineering

by Adam Gregory

In vivo cell therapy is emerging as a groundbreaking approach to reduce the cost and expand the availability of cell therapies. Unlike traditional ex vivo approaches where cells are extracted, ...

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

by Rebecca Tollervey

We are delighted to release our latest report Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know. View the report here.

Forward Magazines 4

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.